Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?
DeCara
J M
JM
Croze
S
S
Falk
R H
RH
D000368:Aged; D000925:Anticoagulants / Q000737:chemistry / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D001682:Biological Availability; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D016568:Drugs, Generic / Q000191:economics; D006801:Humans; D018579:Patient Selection; D013810:Therapeutic Equivalency; D013923:Thromboembolism / Q000517:prevention & control; D014859:Warfarin / Q000737:chemistry / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000925:Anticoagulants; D016568:Drugs, Generic; D014859:Warfarin